Integral Diagnostics Limited (ASX:IDX)
Australia · Delayed Price · Currency is AUD | Market Cap | 819.47M -2.6% |
| Revenue (ttm) | 767.82M +56.3% |
| Net Income | 14.03M +147.8% |
| EPS | 0.04 +59.8% |
| Shares Out | 372.49M |
| PE Ratio | 58.64 |
| Forward PE | 15.51 |
| Dividend | 0.07 (3.27%) |
| Ex-Dividend Date | Mar 4, 2026 |
| Volume | 907,770 |
| Average Volume | 701,654 |
| Open | 2.220 |
| Previous Close | 2.230 |
| Day's Range | 2.180 - 2.220 |
| 52-Week Range | 2.170 - 3.070 |
| Beta | 0.15 |
| RSI | 38.93 |
| Earnings Date | Aug 25, 2026 |
About Integral Diagnostics
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as x-ray and EOS. Integral Diagnostics Limited was founded in 1967 and is headquartered in Melbourne, Australia. [Read more]
Financial Performance
Financial StatementsNews
Integral Diagnostics Ltd (ASX:IDX) (Q1 2026) Earnings Call Highlights: Robust Growth and ...
Integral Diagnostics Ltd (ASX:IDX) (Q1 2026) Earnings Call Highlights: Robust Growth and Strategic Synergies Drive Performance
Half Year 2026 Integral Diagnostics Ltd Earnings Call Transcript
Half Year 2026 Integral Diagnostics Ltd Earnings Call Transcript
Integral Diagnostics Earnings Call Transcript: H1 2026
Revenue grew 55.6% to AUD 393.5 million, with EBITDA margin up 230 bps to 20.6% and strong synergy realization from the Capitol merger. Ongoing investments in AI, teleradiology, and new sites support further growth, while integration costs are trending down.
Integral Diagnostics Transcript: AGM 2025
The meeting highlighted strong revenue and margin growth, successful Capital Health merger integration, and robust sustainability and governance initiatives. Shareholders approved all resolutions, with a focus on radiologist recruitment, AI adoption, and continued industry expansion.
Integral Diagnostics Earnings Call Transcript: H2 2025
Revenue grew 33.7% to $628M, driven by the Capital Health merger and organic growth, with EBITDA margin up to 20.1%. Annualized merger synergies are now $14M, and FY 2026 guidance points to further margin and revenue expansion, supported by MRI deregulation and new screening programs.
Integral Diagnostics Ltd (ASX:IDX) (H1 2025) Earnings Call Highlights: Strong Revenue Growth ...
Integral Diagnostics Ltd (ASX:IDX) (H1 2025) Earnings Call Highlights: Strong Revenue Growth Amidst Challenges
Half Year 2025 Integral Diagnostics Ltd Earnings Call Transcript
Half Year 2025 Integral Diagnostics Ltd Earnings Call Transcript
Integral Diagnostics Earnings Call Transcript: H1 2025
Revenue and EBITDA grew solidly, with strong NPAT and free capital flow, though margins were pressured by regional labor costs and contract caps. Merger synergies, MRI deregulation, and the lung cancer screening program are expected to drive future growth and margin improvement.
Integral Diagnostics Transcript: AGM 2024
The AGM covered a year of solid operational improvement, with revenue and EBITDA growth despite a statutory loss from a New Zealand impairment. Strategic focus included a major merger, board renewal, and ESG progress. All resolutions were presented and voting proceeded smoothly.
Integral Diagnostics Ltd (ASX:IDX) Q2 2024 Earnings Call Transcript Highlights: Solid Revenue ...
Integral Diagnostics Ltd (ASX:IDX) Q2 2024 Earnings Call Transcript Highlights: Solid Revenue Growth Amidst Cost Pressures
Integral Diagnostics Ltd (ASX:IDX) Q4 2024 Earnings Call Transcript Highlights: Strong Revenue ...
Integral Diagnostics Ltd (ASX:IDX) Q4 2024 Earnings Call Transcript Highlights: Strong Revenue Growth Amidst Challenges
Full Year 2024 Integral Diagnostics Ltd Earnings Call Transcript
Full Year 2024 Integral Diagnostics Ltd Earnings Call Transcript
Integral Diagnostics Earnings Call Transcript: H2 2024
Revenue grew 6.6% to AUD 469.7M and operating EBITDA rose 7.4% to AUD 91.5M, with improved margins and strong free cash flow. A statutory loss was recorded due to a New Zealand impairment, but the outlook is positive with a major merger and regulatory changes expected to drive growth.
Integral Diagnostics Transcript: M&A Announcement
A transformative merger will create a leading diagnostic imaging provider in ANZ, combining complementary networks and unlocking at least AUD 10 million in annual cost synergies. The deal is expected to deliver double-digit EPS accretion, with minimal regulatory hurdles anticipated.
Integral Diagnostics Transcript: M&A Announcement
A merger is proposed to create a leading diagnostic imaging group in Australia and New Zealand, offering significant scale, clinical depth, and at least AUD 10 million in annual cost synergies. The deal is structured as a share exchange, with integration and regulatory approvals expected over several months.